Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus ELDECORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus ELDECORT.
ARAZLO vs ELDECORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Corticosteroid binding to glucocorticoid receptors, leading to anti-inflammatory and immunosuppressive effects via inhibition of phospholipase A2, reduction of prostaglandins and leukotrienes, and modulation of cytokine production.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Initial: 5-60 mg orally once daily, adjusted based on response; typical maintenance: 5-15 mg orally once daily.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal elimination half-life is 3.5 ± 1.2 hours in adults with normal renal function; prolonged to 6–8 hours in severe renal impairment (CrCl <30 mL/min).
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Renal excretion of unchanged drug accounts for approximately 60% of the dose; fecal elimination contributes about 30% due to biliary secretion; the remaining 10% is metabolized.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid